This study aimed to identify treatment outcomes and prognostic factors for IDH-WT histological grade 2/3 astrocytomas with molecular features of glioblastoma, IDH-wildtype, CNS WHO grade 4, and to capture changing treatment trends. This evidence concerns the gene IDH1 and glioblastoma.